Versant carefully sets the stage for a $68M debut of a biotech player focused on synthetic lethality
Over the past 18 months, the growing team at Repare Therapeutics has been quietly setting up shop in Versant Ventures’ discovery ops and focusing on synthetic lethality — the therapeutic interplay between genetic mutations and cancer. Using CRISPR gene editing tech as an interrogation tool, they’ve been playing with well known targets like p53 and BRCA1 to find out how they conspire with other mutations in the destruction of a malignancy, following the trail of lesions in the pursuit of new therapies that can work in the same fundamental way those PARP inhibitors you’ve been hearing so much about can fight cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.